Download PDF
Thromb Haemost 2004; 92(01): 178-184
DOI: 10.1160/TH03-11-0674
Cell Signalling and Vessel Remodelling
Schattauer GmbH

Coagulation activation in young survivors of myocardial infarction (MI) - a population-based case-control study

Ellen Brodin
1   Center for Atherothrombotic Research in Tromsø (CART), Department of Medicine, Institute of Clinical Medicine, University of Tromsø,Tromsø, Norway
,
Trond Børvik
1   Center for Atherothrombotic Research in Tromsø (CART), Department of Medicine, Institute of Clinical Medicine, University of Tromsø,Tromsø, Norway
,
Per Morten Sandset
2   Haematological Research Laboratory, Medical Clinic, Ullevaal University Hospital, Oslo, Norway
,
Kaare H. Bønaa
3   Institute of Community Medicine, University of Tromsø,Tromsø, Norway
,
Arne Nordøy
1   Center for Atherothrombotic Research in Tromsø (CART), Department of Medicine, Institute of Clinical Medicine, University of Tromsø,Tromsø, Norway
,
John-Bjarne Hansen
1   Center for Atherothrombotic Research in Tromsø (CART), Department of Medicine, Institute of Clinical Medicine, University of Tromsø,Tromsø, Norway
› Author AffiliationsFinancial support: CART is supported by an independent grant from Pfizer Norway AS.
Further Information

Publication History

Received 05 November 2003

Accepted after revision 02 April 2004

Publication Date:
29 November 2017 (online)

    Permissions and Reprints

Summary

Formation of an occlusive thrombus by exposure of tissue factor (TF) to circulating blood and subsequent triggering of coagulation by TF-FVIIa complexes on ruptured atherosclerotic plaques is thought to be a key event in acute MI. Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of TF-induced coagulation by neutralizing FXa and inhibiting the TF-FVIIa complex. A case control study was conducted to investigate the role of coagulation activation in MI. Sixty-two patients with verified MI, 40-60 yrs of age, were recruited into the study and examined 1-4 years after the acute coronary event. Thrombinantithrombin complex (TAT) was significantly increased in MI patients (8.2 ± 12.9 µg/l vs. 3.9 ± 2.6 µg/l, p=0.01). In contrast, FVIIa was lower in MI patients (41 ± 13 mU/ml vs. 48 ± 15 mU/ml, p=0.003) accompanied by an increase in plasma free TFPI antigen (20.9 ± 5.0 ng/ml vs. 19.2 ± 4.9 ng/ml, p=0.03). Significant trends for increase in triglycerides and total cholesterol across quartiles of free TFPI Ag were found in both groups, whereas HDL cholesterol decreased across quartiles of TFPI among control subjects. The compensatory increase in plasma free TFPI with established lipid and haemostatic risk factors were abrogated in the MI patients. An apparent increase in the basal activation of the coagulation system was observed in young patients with MI. Enhanced coagulation activation was accompanied by a decrease in FVIIa and increase in free TFPI Ag, probably reflecting a modest triggering of TF-induced coagulation in these patients.

Keywords

Tissue factor pathway inhibitor (TFPI) - tissue factor / factor VII - ischaemic heart disease - thrombin
 

  • References

  • 1 Tremoli E, Camera M, Toschi V. et al. Tissue factor in atherosclerosis. Atherosclerosis 1999; 144: 273-83.
    CrossrefPubMedGoogle Scholar
  • 2 Fuster V, Badimon L, Badimon JJ. et al. The pathogenesis of coronary artery disease and the acute coronary syndrome. N Engl J Med 1992; 326: 310-8.
    CrossrefPubMedGoogle Scholar
  • 3 Wilcox JN, Smith KM, Schwartz SM. et al. Localization of tissue factor in normal vessel and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-43.
    CrossrefPubMedGoogle Scholar
  • 4 Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-4.
    CrossrefPubMedGoogle Scholar
  • 5 Suefuji K, Ogawa H, Yasue H. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997; 134: 253-9.
    CrossrefPubMedGoogle Scholar
  • 6 Misumi K, Ogawa H, Yasue H. Comparison of plasma tissue factor levels in unstable and stable angina pectoris. Am J Cardiol 1998; 81: 22-6.
    CrossrefPubMedGoogle Scholar
  • 7 Broze Jr. GJ, Warren LA, Novotny WF. et al. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1988; 71: 335-43.
    PubMedGoogle Scholar
  • 8 Warn-Cramer BJ, Rao LVM, Maki SL. et al. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb Haemost 1988; 60: 453-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Van de Loo J. Annotation. Circulating factors of the haemostatic system as indicators of increased or reduced coronary risk. Br J Haematol 1995; 91: 777-82.
    CrossrefPubMedGoogle Scholar
  • 10 Bajaj MS, Kuppuswamy MN, Saito H. et al. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869-73.
    CrossrefPubMedGoogle Scholar
  • 11 Falciani M, Gori AM, Fedi S. et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischemic heart disease patients. Thromb Haemost 1998; 79: 495-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Nakagaki T, Foster DC, Berkner KL. et al. Initiation of the extrinsic pathway of blood coagulation: evidence for the tissue factor dependent auto activation of human coagulation factor VII. Biochemistry 1991; 30: 10819-24.
    CrossrefPubMedGoogle Scholar
  • 13 de Sousa JCarvalho, Azvedo J, Soria C. et al. Factor VII hyperactivity in acute myocardial thrombosis: a relation to the coagulation activation. Thromb Res 1988; 51: 165-73.
    CrossrefPubMedGoogle Scholar
  • 14 Miller GJ, Bauer KA, Barzegar S. et al. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost 1996; 75: 767-77.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Moor E, Silveira A, Hooft FV. et al. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vasc Biol 1995; 15: 655-64.
    CrossrefPubMedGoogle Scholar
  • 16 Merlini PA, Bauer K, Oltrona L. et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-8.
    CrossrefPubMedGoogle Scholar
  • 17 Li YH, Teng JK, Tsai WC. et al. Prognostic significance of elevated haemostatic markers in patients with acute myocardial infarction. J Am Coll Cardiol 1999; 33: 1543-8.
    CrossrefPubMedGoogle Scholar
  • 18 Peternel P, Terbizan M, Tratar G. et al. Markers of haemostatic system activation during treatment of deep vein thrombosis with subcutaneous unfractionated or low molecular weight heparin. Thromb Res 2002; 105: 241-6.
    CrossrefPubMedGoogle Scholar
  • 19 Burstein M, Scholnick HR, Mofin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyamines. J Lipid Res 1970; 11: 583-95.
    PubMedGoogle Scholar
  • 20 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifugation. Clin Chem 1972; 18: 499-502.
    PubMedGoogle Scholar
  • 21 Sandset PM, Larsen ML, Abildgaard U. et al. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis 1991; 2: 425-33.
    CrossrefPubMedGoogle Scholar
  • 22 Østergaard PB, Beck TC, Ørsted H. et al. An enzyme linked immunosorption assay for tissue factor pathway inhibitor. Thromb Res 1997; 87: 447-59.
    CrossrefPubMedGoogle Scholar
  • 23 Morrisey JH, Marci BG, Neuenschwander PF. et al. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
    PubMedGoogle Scholar
  • 24 Ottani F, Galvani M. Prognostic role of haemostatic markers in acute coronary syndrome patients. Clinica Chimica Acta 2001; 311: 33-9.
    CrossrefPubMedGoogle Scholar
  • 25 Danielsen R, Onundarson P, Thors H. et al. Activated and total coagulation factor VII, and fibrinogen in coronary artery disease. Scand Cardiovasc 1998; 32: 87-95.
    PubMedGoogle Scholar
  • 26 Moor E, Silveira A, Hooft FV. et al. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Arterioscler Thromb Vasc Biol 1995; 15: 655-64.
    CrossrefPubMedGoogle Scholar
  • 27 Cooper JA, Miller GJ, Bauer KA. et al. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 2000; 102: 2816-22.
    CrossrefPubMedGoogle Scholar
  • 28 Golino P. The inhibitors of the tissue factor: factor VII pathway. Thromb Res 2002; 106: 257-65.
    CrossrefPubMedGoogle Scholar
  • 29 Mesters RM, Mannucci PM, Coppola R. et al. Factor VIIa and antithrombin III activity during servere sepsis and septic shock in neutropenic patients. Blood 1996; 88: 881-6.
    PubMedGoogle Scholar
  • 30 Rapaport SI, Rao LVM. The tissue factor pathway: How it has become a “prima ballerina”. Thromb Haemost 1995; 74: 7-17.
    PubMedGoogle Scholar
  • 31 Almus FE, Rao LVM, Rapaport SI. Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model. Arterioscler Thromb Vasc Biol 1993; 13: 105-11.
    CrossrefPubMedGoogle Scholar
  • 32 Kawaguchi A, Miyao Y, Noguchi T. et al. Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase but proportional to apolipoprotein A-II. Arterioscler Thromb Vasc Biol 2000; 20: 251-8.
    CrossrefPubMedGoogle Scholar
  • 33 Saigo M, Abe S, Ogawa M. et al. Imbalance of plasminogen activator inhibitor -1/tissue plasminogen activator and tissue factor/ tissue factor pathway inhibitor in young Japanese men with myocardial infarction. Thromb Haemost 2001; 86: 1197-203.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Hansen JB, Grimsgaard S, Huseby NE. et al. Serum lipids and regulation of tissue factor-nduced coagulation in middle-aged men. Thromb Res 2001; 102: 3-13.
    CrossrefPubMedGoogle Scholar
  • 35 Hansen JB, Huseby NE, Sandset PM. et al. Tissue factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb Vasc Biol 1994; 14: 223-9.
    CrossrefPubMedGoogle Scholar
  • 36 Kokawa T, Abumiya T, Kimura T. et al. Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipidemia. Arterioscler Thromb Vasc Biol 1995; 15: 504-10.
    CrossrefPubMedGoogle Scholar